Drugs / LY3962681
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06565195 | Aug 2024 → May 2029 expected | Parkinson disease | Prevail Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3962681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06565195 ↗ |
| Route | Intrathecal | “administered intrathecally (into the spinal fluid)” NCT06565195 ↗ |